Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Stormlund, Sacha ; Sopa, Negjyp ; Zedeler, Anne ; Bogstad, Jeanette ; Prætorius, Lisbeth ; Nielsen, Henriette Svarre ; Kitlinski, Margaretha Laczna ; Skouby, Sven O ; Mikkelsen, Anne Lis ; Spangmose, Anne Lærke ; Jeppesen, Janni Vikkelsø ; Khatibi, Ali ; la Cour Freiesleben, Nina ; Ziebe, Søren ; Polyzos, Nikolaos P ; Bergh, Christina ; Humaidan, Peter ; Andersen, Anders Nyboe ; Løssl, Kristine ; Pinborg, Anja. / Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles : multicentre randomised controlled trial. In: BMJ. 2020 ; Vol. 370.

Bibtex

@article{89f36c365f56437aa077af2b997ed136,
title = "Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial",
abstract = "OBJECTIVE: To compare the ongoing pregnancy rate between a freeze-all strategy and a fresh transfer strategy in assisted reproductive technology treatment.DESIGN: Multicentre, randomised controlled superiority trial.SETTING: Outpatient fertility clinics at eight public hospitals in Denmark, Sweden, and Spain.PARTICIPANTS: 460 women aged 18-39 years with regular menstrual cycles starting their first, second, or third treatment cycle of in vitro fertilisation or intracytoplasmic sperm injection.INTERVENTIONS: Women were randomised at baseline on cycle day 2 or 3 to one of two treatment groups: the freeze-all group (elective freezing of all embryos) who received gonadotropin releasing hormone agonist triggering and single frozen-thawed blastocyst transfer in a subsequent modified natural cycle; or the fresh transfer group who received human chorionic gonadotropin triggering and single blastocyst transfer in the fresh cycle. Women in the fresh transfer group with more than 18 follicles larger than 11 mm on the day of triggering had elective freezing of all embryos and postponement of transfer as a safety measure.MAIN OUTCOME MEASURES: The primary outcome was the ongoing pregnancy rate defined as a detectable fetal heart beat after eight weeks of gestation. Secondary outcomes were live birth rate, positive human chorionic gonadotropin rate, time to pregnancy, and pregnancy related, obstetric, and neonatal complications. The primary analysis was performed according to the intention-to-treat principle.RESULTS: Ongoing pregnancy rate did not differ significantly between the freeze-all and fresh transfer groups (27.8{\%} (62/223) v 29.6{\%} (68/230); risk ratio 0.98, 95{\%} confidence interval 0.87 to 1.10, P=0.76). Additionally, no significant difference was found in the live birth rate (27.4{\%} (61/223) for the freeze-all group and 28.7{\%} (66/230) for the fresh transfer group; risk ratio 0.98, 95{\%} confidence interval 0.87 to 1.10, P=0.83). No significant differences between groups were observed for positive human chorionic gonadotropin rate or pregnancy loss, and none of the women had severe ovarian hyperstimulation syndrome; only one hospital admission related to this condition occurred in the fresh transfer group. The risks of pregnancy related, obstetric, and neonatal complications did not differ between the two groups except for a higher mean birth weight after frozen blastocyst transfer and an increased risk of prematurity after fresh blastocyst transfer. Time to pregnancy was longer in the freeze-all group.CONCLUSIONS: In women with regular menstrual cycles, a freeze-all strategy with gonadotropin releasing hormone agonist triggering for final oocyte maturation did not result in higher ongoing pregnancy and live birth rates than a fresh transfer strategy. The findings warrant caution in the indiscriminate application of a freeze-all strategy when no apparent risk of ovarian hyperstimulation syndrome is present.TRIAL REGISTRATION: Clinicaltrials.gov NCT02746562.",
author = "Sacha Stormlund and Negjyp Sopa and Anne Zedeler and Jeanette Bogstad and Lisbeth Pr{\ae}torius and Nielsen, {Henriette Svarre} and Kitlinski, {Margaretha Laczna} and Skouby, {Sven O} and Mikkelsen, {Anne Lis} and Spangmose, {Anne L{\ae}rke} and Jeppesen, {Janni Vikkels{\o}} and Ali Khatibi and {la Cour Freiesleben}, Nina and S{\o}ren Ziebe and Polyzos, {Nikolaos P} and Christina Bergh and Peter Humaidan and Andersen, {Anders Nyboe} and Kristine L{\o}ssl and Anja Pinborg",
note = "{\circledC} Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = "8",
day = "5",
doi = "10.1136/bmj.m2519",
language = "English",
volume = "370",
journal = "BMJ",
issn = "1756-1833",
publisher = "B M J Group",

}

RIS

TY - JOUR

T1 - Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles

T2 - multicentre randomised controlled trial

AU - Stormlund, Sacha

AU - Sopa, Negjyp

AU - Zedeler, Anne

AU - Bogstad, Jeanette

AU - Prætorius, Lisbeth

AU - Nielsen, Henriette Svarre

AU - Kitlinski, Margaretha Laczna

AU - Skouby, Sven O

AU - Mikkelsen, Anne Lis

AU - Spangmose, Anne Lærke

AU - Jeppesen, Janni Vikkelsø

AU - Khatibi, Ali

AU - la Cour Freiesleben, Nina

AU - Ziebe, Søren

AU - Polyzos, Nikolaos P

AU - Bergh, Christina

AU - Humaidan, Peter

AU - Andersen, Anders Nyboe

AU - Løssl, Kristine

AU - Pinborg, Anja

N1 - © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/8/5

Y1 - 2020/8/5

N2 - OBJECTIVE: To compare the ongoing pregnancy rate between a freeze-all strategy and a fresh transfer strategy in assisted reproductive technology treatment.DESIGN: Multicentre, randomised controlled superiority trial.SETTING: Outpatient fertility clinics at eight public hospitals in Denmark, Sweden, and Spain.PARTICIPANTS: 460 women aged 18-39 years with regular menstrual cycles starting their first, second, or third treatment cycle of in vitro fertilisation or intracytoplasmic sperm injection.INTERVENTIONS: Women were randomised at baseline on cycle day 2 or 3 to one of two treatment groups: the freeze-all group (elective freezing of all embryos) who received gonadotropin releasing hormone agonist triggering and single frozen-thawed blastocyst transfer in a subsequent modified natural cycle; or the fresh transfer group who received human chorionic gonadotropin triggering and single blastocyst transfer in the fresh cycle. Women in the fresh transfer group with more than 18 follicles larger than 11 mm on the day of triggering had elective freezing of all embryos and postponement of transfer as a safety measure.MAIN OUTCOME MEASURES: The primary outcome was the ongoing pregnancy rate defined as a detectable fetal heart beat after eight weeks of gestation. Secondary outcomes were live birth rate, positive human chorionic gonadotropin rate, time to pregnancy, and pregnancy related, obstetric, and neonatal complications. The primary analysis was performed according to the intention-to-treat principle.RESULTS: Ongoing pregnancy rate did not differ significantly between the freeze-all and fresh transfer groups (27.8% (62/223) v 29.6% (68/230); risk ratio 0.98, 95% confidence interval 0.87 to 1.10, P=0.76). Additionally, no significant difference was found in the live birth rate (27.4% (61/223) for the freeze-all group and 28.7% (66/230) for the fresh transfer group; risk ratio 0.98, 95% confidence interval 0.87 to 1.10, P=0.83). No significant differences between groups were observed for positive human chorionic gonadotropin rate or pregnancy loss, and none of the women had severe ovarian hyperstimulation syndrome; only one hospital admission related to this condition occurred in the fresh transfer group. The risks of pregnancy related, obstetric, and neonatal complications did not differ between the two groups except for a higher mean birth weight after frozen blastocyst transfer and an increased risk of prematurity after fresh blastocyst transfer. Time to pregnancy was longer in the freeze-all group.CONCLUSIONS: In women with regular menstrual cycles, a freeze-all strategy with gonadotropin releasing hormone agonist triggering for final oocyte maturation did not result in higher ongoing pregnancy and live birth rates than a fresh transfer strategy. The findings warrant caution in the indiscriminate application of a freeze-all strategy when no apparent risk of ovarian hyperstimulation syndrome is present.TRIAL REGISTRATION: Clinicaltrials.gov NCT02746562.

AB - OBJECTIVE: To compare the ongoing pregnancy rate between a freeze-all strategy and a fresh transfer strategy in assisted reproductive technology treatment.DESIGN: Multicentre, randomised controlled superiority trial.SETTING: Outpatient fertility clinics at eight public hospitals in Denmark, Sweden, and Spain.PARTICIPANTS: 460 women aged 18-39 years with regular menstrual cycles starting their first, second, or third treatment cycle of in vitro fertilisation or intracytoplasmic sperm injection.INTERVENTIONS: Women were randomised at baseline on cycle day 2 or 3 to one of two treatment groups: the freeze-all group (elective freezing of all embryos) who received gonadotropin releasing hormone agonist triggering and single frozen-thawed blastocyst transfer in a subsequent modified natural cycle; or the fresh transfer group who received human chorionic gonadotropin triggering and single blastocyst transfer in the fresh cycle. Women in the fresh transfer group with more than 18 follicles larger than 11 mm on the day of triggering had elective freezing of all embryos and postponement of transfer as a safety measure.MAIN OUTCOME MEASURES: The primary outcome was the ongoing pregnancy rate defined as a detectable fetal heart beat after eight weeks of gestation. Secondary outcomes were live birth rate, positive human chorionic gonadotropin rate, time to pregnancy, and pregnancy related, obstetric, and neonatal complications. The primary analysis was performed according to the intention-to-treat principle.RESULTS: Ongoing pregnancy rate did not differ significantly between the freeze-all and fresh transfer groups (27.8% (62/223) v 29.6% (68/230); risk ratio 0.98, 95% confidence interval 0.87 to 1.10, P=0.76). Additionally, no significant difference was found in the live birth rate (27.4% (61/223) for the freeze-all group and 28.7% (66/230) for the fresh transfer group; risk ratio 0.98, 95% confidence interval 0.87 to 1.10, P=0.83). No significant differences between groups were observed for positive human chorionic gonadotropin rate or pregnancy loss, and none of the women had severe ovarian hyperstimulation syndrome; only one hospital admission related to this condition occurred in the fresh transfer group. The risks of pregnancy related, obstetric, and neonatal complications did not differ between the two groups except for a higher mean birth weight after frozen blastocyst transfer and an increased risk of prematurity after fresh blastocyst transfer. Time to pregnancy was longer in the freeze-all group.CONCLUSIONS: In women with regular menstrual cycles, a freeze-all strategy with gonadotropin releasing hormone agonist triggering for final oocyte maturation did not result in higher ongoing pregnancy and live birth rates than a fresh transfer strategy. The findings warrant caution in the indiscriminate application of a freeze-all strategy when no apparent risk of ovarian hyperstimulation syndrome is present.TRIAL REGISTRATION: Clinicaltrials.gov NCT02746562.

U2 - 10.1136/bmj.m2519

DO - 10.1136/bmj.m2519

M3 - Journal article

VL - 370

JO - BMJ

JF - BMJ

SN - 1756-1833

ER -

ID: 60613905